INVERSAGO-PHARMA
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.
This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome. Topline results from 40 subjects are expected in the second half of the calendar year.
“We are pleased that the clinical trials for INV-202, our first-in-class, peripheral CB1 inhibitor, are moving ahead swiftly,” said Dr. François Ravenelle, Chief Executive Officer of Inversago. “This pharmacokinetic and safety study will also measure a number of well accepted biomarkers of metabolic disorders. Together, these results are expected to act as a guide for the next phase of INV-202’s development.”
Inversago is planning to launch its first Phase 2 study in patients with Diabetic Nephropathy (DN) shortly after results are available. DN involves a chronic loss of kidney function in people with type-1 and type-2 diabetes who also often present obesity. This patient profile allows for the objective measurement of primary endpoints specific to DN and secondary endpoints relevant to metabolic diseases at large. The company believes that this choice of indication provides the optimal proof of concept to demonstrate the therapeutic breadth of opportunity available to INV-202 and the rest of the Inversago pipeline.
Peripheral CB1 inverse agonists, such as Inversago’s lead INV-202 molecule, have demonstrated efficacy in addressing multiple pathways involved in renal injury. Aside effects on albuminuria in pre-clinical models, CB1 inverse agonists have shown clinical improvements in lipids, weight loss and glucose. Each of these effects have separately demonstrated reno-protective characteristics.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF). For more information, visit inversago.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005525/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Achieves the AWS Agentic AI Specialization and Is Named an Implementation Partner for Amazon Bedrock AgentCore9.12.2025 10:47:00 CET | Press release
Reply [EXM, STAR: REY] announced that it has achieved the Amazon Web Services (AWS) Agentic AI Specialization, a new category within the AWS AI Competency. This recognition positions Reply and its companies specialized in AWS technologies - Data Reply and Storm Reply - among the AWS Partners able to help customers deploy smart, self-operating AI systems that can think, plan, and act autonomously to execute complex business processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209601808/en/ Through Amazon Bedrock AgentCore, organizations can simplify and secure the development of intelligent agents at scale, interact with enterprise systems, analyze data in real time, and automate complex processes. The specialization further strengthens Reply’s long-standing expertise in AWS technologies and its ability to deliver production-ready autonomous AI systems based on Amazon Bedrock Agents and AWS-native frameworks, enabling
LabelVie Advances AI-Driven Grocery Retail Transformation Through Long-Standing Collaboration with SymphonyAI9.12.2025 10:00:00 CET | Press release
Longstanding collaboration powers data-driven supply chain innovation, driving measurable ROI and operational agility across LabelVie’s growing retail footprint For more than two decades, LabelVie Group has relied on SymphonyAI, a global leader in Vertical AI product platforms, to power its grocery retail transformation. Now, that partnership is entering a new phase — one defined by connected intelligence, predictive precision, and measurable impact across LabelVie’s 270-plus stores in Morocco and Ivory Coast. As one of North Africa’s largest and fastest-growing grocery retail and wholesale operators, LabelVie is advancing its digital modernization through SymphonyAI’s end-to-end retail solutions, which support greater visibility, accuracy, and operational coordination across its growing network. The continued collaboration reinforces a long-term commitment to improving supply-chain processes and store operations as LabelVie expands into new markets and grocery retail formats. “Symphon
INNIO wins prestigious German Sustainability Award 20269.12.2025 09:07:00 CET | Press release
INNIO Group has been awarded the German Sustainability Award for Companies 2026. At the 18th annual ceremony in Düsseldorf, INNIO was named winner in the “Engines and Turbines” category within the “Machines and Installations” sector. Recognized as one of Europe’s most respected distinctions for corporate responsibility, the German Sustainability Award reflects the United Nations’ Agenda 2030 and thus on the key areas of transformation such as climate, biodiversity, resources, supply chain, and society. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205520809/en/ INNIO wins prestigious German Sustainability Award 2026 (c) Frank Fendler “This award is a tremendous recognition for our entire team and validates our 360-degree approach to sustainable innovation throughout the value chain,” said Marcin Kawa, VP Sustainability at INNIO Group. “We are committed to actively shaping the energy transition and delivering solutions th
EURONICS and NIQ Forge Strategic Collaboration to Elevate Retail Pricing Intelligence9.12.2025 09:00:00 CET | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company combined with GfK in 2023, has been selected by EURONICS, a leading global shopping cooperative in the Technical Consumer Goods (TCG) sector, to provide comprehensive Online Price Monitoring. NIQ's Online Price Monitoring provides insights into pricing dynamics by tracking item-level pricing across a defined data set. The system captures product information, matches items accurately, and ensures quality through advanced automated processes combined with human oversight and detailed checks. NIQ offers a range of retail pricing solutions, including pricing intelligence tools and the Consumer Price Lab, empowering businesses to make informed decisions and optimize their pricing strategies. This collaboration focuses on providing EURONICS with comprehensive pricing insights to support informed decision-making. NIQ delivers accurate and transparent data to help EURONICS understand market dynamics and plan effectively. "Through our col
SonicEdge and Earfab Partner to Shape the Future of Personalized Audio and Hearing Wellness9.12.2025 09:00:00 CET | Press release
Partnership unites SonicEdge’s micro-speaker technology with Earfab’s custom-fit innovation to deliver unmatched comfort and fidelity SonicEdge, a pioneer in micro-acoustic innovation, today announced a strategic partnership with Earfab, the innovator of custom-fit hearing technology, to co-develop a new generation of personalized audio solutions that unite comfort, precision, and hearing safety. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209472421/en/ Credit: SonicEdge By combining SonicEdge’s high-performance MEMS speaker-in-chip technology with Earfab’s custom-fit eartips – crafted using its proprietary earfabSCAN 3D smartphone scanning platform – the collaboration delivers a first-of-its-kind experience that redefines in-ear performance. The joint solution provides a perfect acoustic seal for enhanced sound fidelity, improved active noise cancellation, and long-term listening comfort – without compromising hearing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom